Biomarker Assay Logistics In BATTLE And Lung-MAP

Why Laboratory Logistics Are Part of Trial Design

A precision-medicine platform can have a scientifically compelling treatment strategy and still fail operationally if it cannot obtain tissue, return assay results in time, or identify enough eligible participants. In a biomarker-based trial, the laboratory pathway is not merely a supporting service: it determines who can be assigned, when assignment can occur, and how much recruitment effort produces an analysable participant.

BATTLE and Lung-MAP illustrate two different settings for this problem. BATTLE, conducted at a single cancer center in advanced non-small-cell lung cancer (NSCLC), required a pretreatment tumor biopsy and used biomarker information in an adaptive treatment-allocation strategy. Lung-MAP was a multi-center screening platform for advanced squamous NSCLC. Its original structure used centralized tumor testing to direct participants to biomarker-defined substudies. The comparison is not simply “one assay versus another”: the biopsy pathway, scale of the network, tissue source, testing organization, and consequences of an unavailable result all matter.

Two Trial Workflows

In BATTLE, participants with advanced NSCLC underwent a mandatory biopsy before treatment assignment. Tumor samples were profiled for biomarkers, and the results informed assignment among treatment options. The study’s adaptive randomization used accumulating outcome information to change the probabilities of assignment within biomarker-defined groups. Operationally, this meant that tissue collection and profiling had to occur early enough to support assignment, while the trial also needed a continuing supply of participants and sufficiently complete response data to support adaptation. BATTLE is often described as having a biomarker-assay turnaround target of about two weeks; the practical interval for an individual participant could also include scheduling, biopsy, specimen processing, and reporting.

Lung-MAP organized screening across a larger network. In its original design for advanced squamous NSCLC, centralized genomic testing of tumor tissue directed participants to biomarker-defined substudies. Tissue from an earlier diagnostic procedure could sometimes be used if it met protocol and laboratory requirements; when available tissue was inadequate or unsuitable, obtaining additional tissue could become necessary. Central testing made consistent screening across sites possible, but it also made specimen transport, laboratory capacity, and communication of results important parts of the pathway. A report that arrives after clinical deterioration or a treatment decision may be analytically valid yet operationally unusable.

The key distinction is therefore not that one platform had logistics and the other did not. BATTLE placed a substantial requirement on obtaining a new pretreatment sample in a single-center setting. Lung-MAP had to coordinate tissue screening and result-based assignment across a multi-center network, with the possibility that existing tissue could avoid a new biopsy. Both needed a reliable route from an appropriate specimen to an actionable result.

From a Specimen to an Assignable Participant

A useful way to assess a workflow is to separate its sequential steps. Let \(p_B\) be the probability that a candidate can provide the required tissue safely, \(p_A\) the probability that the specimen is adequate for the assay, and \(p_T\) the probability that a usable result returns within the protocol’s clinically acceptable time. Let \(p_E\) be the probability that the result meets a treatment group’s biomarker criteria, conditional on having a usable, timely result. If these probabilities are defined conditionally at each step, the probability that a candidate becomes timely and biomarker-eligible is

This multiplication follows from the chain rule: each factor is the probability of passing the next stage given passage through the preceding stages. It does not require the stages to be independent. The conditional definitions are important; multiplying unconditional probabilities that overlap or use different denominators can misstate yield. If \(N\) candidates enter screening, the expected number reaching timely biomarker eligibility is \(N p_B p_A p_T p_E\), provided the probabilities are reasonably stable over that screening period.

This calculation exposes why a high-performing assay does not guarantee an efficient platform. Even if the assay is accurate, a low rate of adequate tissue or a long delay can reduce the number of participants who receive a result in time. Conversely, a high prevalence of a target biomarker does not help if many specimens fail before testing or reports arrive too late for assignment.

Turnaround Time Is a Clinical Constraint

A turnaround target should be defined with explicit start and end points. “Two weeks” might mean two weeks from laboratory receipt to report; it does not automatically include the time required to obtain consent, schedule a biopsy, prepare the specimen, and ship it. For trial operations, record these intervals separately where feasible. Otherwise, a laboratory may appear to meet its target while the participant waits substantially longer from screening to treatment assignment.

The acceptable delay depends on the clinical setting and the protocol. A result may be returned quickly in laboratory terms but arrive after the participant’s condition changes or another treatment must begin. Likewise, a modest delay may be tolerable when participants are clinically stable and a suitable alternative treatment is available. Thus, “timely” is not a universal number; it is a protocol-defined threshold informed by the anticipated clinical course and treatment pathway.

Why the BATTLE–Lung-MAP Comparison Matters

BATTLE’s mandatory pretreatment biopsy made the biological sample temporally relevant to the treatment decision, but imposed a direct burden: participants needed an accessible lesion, a safe procedure, and sufficient tissue. A new biopsy can reduce reliance on old material, yet it can also exclude people who cannot undergo the procedure and create scheduling delays. In an adaptive study, these losses affect more than accrual. They can slow the flow of biomarker-specific outcome data available to inform later assignment probabilities.

Lung-MAP’s central screening model made a common testing pathway possible across sites and linked molecular findings to distinct treatment substudies. Using suitable existing tissue can reduce the need for an additional procedure, but archival specimens may be unavailable, insufficient, or unsuitable for the intended test. Centralization also creates dependencies: shipping delays, incomplete requisitions, laboratory bottlenecks, and communication failures can affect many sites at once. A platform must plan for those delays rather than treat testing as an instantaneous eligibility check.

The operational alternative is not always to abandon biomarker selection. Depending on the scientific question and clinical setting, a protocol might permit suitable archival tissue, use a more efficient validated assay, strengthen local biopsy coordination, expand laboratory capacity, or use a screening group that can be assigned without the biomarker result. Each choice changes the population that can be studied and may change the scientific question. For example, allowing older tissue can improve access but may make the measured biomarker less representative of the tumor at the time of treatment.

Diagnostics, Failure Modes, and Limits

Operational monitoring should follow the participant through the full pathway, not just the assay’s analytic performance. Useful measures include the proportions consented, biopsied, yielding adequate tissue, successfully tested, reported within the target interval, and assigned to a treatment group. Record elapsed times with consistent start and end definitions, and examine them by site and calendar period. A good overall average can conceal a site with repeated failures or a growing queue as enrollment increases.

• Low tissue adequacy: review specimen requirements, collection procedures, and reasons for failure. Do not assume that more screening will solve a systematic collection problem.
• Long or variable turnaround: separate transport time from laboratory processing and reporting. A rising tail of very long delays can be clinically important even if the median remains acceptable.
• Few assignments to a subgroup: distinguish low biomarker prevalence from losses due to biopsy, assay failure, or late results. These require different remedies.
• Uneven site performance: check whether training, shipment procedures, or access to biopsy facilities differ across sites before attributing the pattern to participant characteristics.
• Changing biomarker measurement: document assay and specimen changes. A result from a different test or tissue source may not be directly comparable without appropriate validation.

These operational summaries have limits. Small screening counts produce imprecise rates; an early estimate of turnaround may not predict performance after the platform scales up. Conditional probabilities may change with site mix, tissue type, disease burden, and laboratory workload. The expected yield formula is a planning aid, not a substitute for monitoring actual participant flow or evaluating assay validity.

Common Pitfall

Wrong reasoning: “The assay returns results within two weeks, so eligible participants can be assigned within two weeks.” This treats laboratory turnaround as the entire participant pathway and ignores the time to arrange and perform a biopsy, transport and accession the sample, and act on the report.

Correction: Define the laboratory interval and the full screening-to-assignment interval separately. Assess whether the full pathway meets a clinically justified target, and identify which component causes delay. The BATTLE and Lung-MAP comparison shows why that distinction matters: a tissue requirement and a central testing network create different points of operational vulnerability even when both rely on biomarker results.